STTK — Shattuck Labs, Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 1680367 ·
Last close
$6.11
Market Cap
$468.52M
52W High
$8.33
52W Low
$3.81
ADV30
520,971
Next earnings
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -15,545,000 -14,767,000 102,121,000 90,419,000 6,286,000
Dec 2025 0 -13,371,000 -12,593,000 91,026,000 54,192,000 8,636,000
Sep 2025 1,000,000 -10,716,000 -10,056,000 100,333,000 42,548,000 7,093,000
Jun 2025 0 -13,032,000 -12,458,000 64,371,000 50,467,000 7,352,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-39,882,000
Investing CF
$-7,887,000
Financing CF
$44,574,000
CapEx
$-42,000
Dividends Paid
Buybacks
$0
EPS Diluted TTM
$-0.77
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-430,529,000
Inventory
Receivables
ST Investments
$23,873,000
EBIT TTM
$-51,508,000
Pretax Income TTM
$-48,809,000
Interest Exp TTM
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,000,000
EBITDA
$-48,940,000
Free Cash Flow
$-22,423,376
Enterprise Value
$380,987,968
Total Cash
$90,419,000
Total Debt
$2,889,000
Shares Out
76,680,517
Trailing EPS
$-0.56
Book Value
$1.30
ROE
-61.0%
ROA
-36.7%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 1,000,000 -51,508,000 -48,809,000 91,026,000 8,636,000 -39,882,000
Dec 2024 5,721,000 -80,567,000 -75,410,000 91,049,000 11,423,000 -60,515,000
Dec 2023 1,657,000 -91,957,000 -87,298,000 159,564,000 14,859,000 -81,228,000
Dec 2022 652,000 -103,329,000 -101,945,000 205,324,000 29,167,000 -94,498,000

TTM Snapshot

Revenues TTM
$5,795,000
NetIncome TTM
$-86,261,000
OpCashFlow TTM
$0
Assets (Latest)
$91,049,000
Forward EPS
$-0.51

Peers — same industry

TickerNameMarket CapLastDaily %
EBS Emergent BioSolutions Inc. $471.07M $9.13
CATX Perspective Therapeutics, Inc. $474.43M $4.16
KMDA KAMADA LTD $458.60M $7.95
CYDY CytoDyn Inc. $457.62M $0.34
OVID Ovid Therapeutics Inc. $457.27M $2.45

News headlines (Yahoo Finance, 1h cache)

We're Not Very Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate
2026-05-11 11:33 · Yahoo
Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-05-07 10:15 · Yahoo
Cantor Fitzgerald Initiates Coverage of Shattuck Labs (STTK)
2026-05-01 08:17 · Yahoo
Why Shattuck Labs Stock Soared More Than 53% Higher This Week
2026-03-06 22:02 · Yahoo
Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights
2026-03-05 11:15 · Yahoo
Shattuck Labs Announces Participation in Upcoming March Investor Conferences
2026-02-25 13:00 · Yahoo
Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium
2026-02-06 13:30 · Yahoo
Why Shattuck Labs Stock Soared in December
2026-01-06 03:50 · Yahoo
Several Insiders Invested In Shattuck Labs Flagging Positive News
2026-01-05 13:13 · Yahoo
Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-12-15 21:15 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.